Literature DB >> 23212278

Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia.

Maria Pierro1, Lavinia Ionescu, Tiziana Montemurro, Arul Vadivel, Gaia Weissmann, Gavin Oudit, Derek Emery, Sreedhar Bodiga, Farah Eaton, Bruno Péault, Fabio Mosca, Lorenza Lazzari, Bernard Thébaud.   

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) remains a main complication of extreme prematurity and currently lacks efficient treatment. Rat bone marrow-derived mesenchymal stem cells (MSC) prevent lung injury in an oxygen-induced model of BPD. Human cord is an advantageous source of stem cells that is especially appealing for the treatment of neonatal diseases. The therapeutic benefit after established lung injury and long-term safety of cord-derived stem cells is unknown.
METHODS: Human cord-derived perivascular cells (PCs) or cord blood-derived MSCs were delivered prophylactically or after established alveolar injury into the airways of newborn rats exposed to hyperoxia, a well-established BPD model.
RESULTS: Rat pups exposed to hyperoxia showed the characteristic arrest in alveolar growth with air space enlargement and loss of lung capillaries. PCs and MSCs partially prevented and rescued lung function and structure. Despite therapeutic benefit, cell engraftment was low, suggesting that PCs and MSCs act via a paracrine effect. Accordingly, cell free-derived conditioned media from PCs and MSCs also exerted therapeutic benefit when used either prophylactically or therapeutically. Finally, long-term (6 months) assessment of stem cell or conditioned media therapy showed no adverse lung effects of either strategy, with persistent improvement in exercise capacity and lung structure.
CONCLUSIONS: Human umbilical cord-derived PCs and MSCs exert short- and long-term therapeutic benefit without adverse lung effects in this experimental model and offer new therapeutic options for lung diseases characterised by alveolar damage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212278     DOI: 10.1136/thoraxjnl-2012-202323

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  98 in total

Review 1.  MSC microvesicles for the treatment of lung disease: a new paradigm for cell-free therapy.

Authors:  Konstantinos Sdrimas; Stella Kourembanas
Journal:  Antioxid Redox Signal       Date:  2014-02-24       Impact factor: 8.401

Review 2.  Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Authors:  Michael A Matthay; Piero Anversa; Jahar Bhattacharya; Bruce K Burnett; Harold A Chapman; Joshua M Hare; Derek J Hei; Andrew M Hoffman; Stella Kourembanas; David H McKenna; Luis A Ortiz; Harald C Ott; William Tente; Bernard Thébaud; Bruce C Trapnell; Daniel J Weiss; Jason X-J Yuan; Carol J Blaisdell
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

Review 3.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

4.  Stem cells and cell therapies in lung biology and diseases: conference report.

Authors:  Daniel J Weiss; Jason H T Bates; Thomas Gilbert; W Conrad Liles; Carolyn Lutzko; Jay Rajagopal; Darwin Prockop
Journal:  Ann Am Thorac Soc       Date:  2013-10

Review 5.  Impaired pulmonary vascular development in bronchopulmonary dysplasia.

Authors:  Christopher D Baker; Steven H Abman
Journal:  Neonatology       Date:  2015-06-05       Impact factor: 4.035

Review 6.  Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Cindy T McEvoy; Lucky Jain; Barbara Schmidt; Steven Abman; Eduardo Bancalari; Judy L Aschner
Journal:  Ann Am Thorac Soc       Date:  2014-04

Review 7.  Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease.

Authors:  Airan Liu; Xiwen Zhang; Hongli He; Li Zhou; Yoshifumi Naito; Shinji Sugita; Jae-Woo Lee
Journal:  Expert Opin Biol Ther       Date:  2019-11-18       Impact factor: 4.388

Review 8.  Upcycling umbilical cords: bridging regenerative medicine with neonatology.

Authors:  Alvaro Moreira; Yasmeen Alayli; Saloni Balgi; Caitlyn Winter; Samuel Kahlenberg; Shamimunisa Mustafa; Peter Hornsby
Journal:  J Matern Fetal Neonatal Med       Date:  2017-11-27

Review 9.  Postnatal inflammation in the pathogenesis of bronchopulmonary dysplasia.

Authors:  Vineet Bhandari
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-02-27

10.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.

Authors:  Gareth R Willis; Angeles Fernandez-Gonzalez; Jamie Anastas; Sally H Vitali; Xianlan Liu; Maria Ericsson; April Kwong; S Alex Mitsialis; Stella Kourembanas
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.